Clinical trials
Lupus Nephritis clinical trials
Below are recruiting lupus nephritis clinical trials, each written for real people, not researchers. We’re tracking 79 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05207358RecruitingPhase 4
Lower steroid use in active lupus kidney inflammation
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
BucharestAges 18–80 - NCT06058078RecruitingPhase 2
Cell therapy for active lupus nephritis
This trial tests a new cell therapy (RY_SW01) for people with active lupus nephritis (kidney inflammation caused by lupus) who haven't responded well to standard treatments. It aims to see if the therapy can help control the disease.
Nanjing, JiangsuAges 18–65 - NCT06406205RecruitingPhase 3
Study of QLG1074 for active lupus nephritis
This trial tests a new medicine called QLG1074 added to standard treatments for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if the combination helps control the disease better.
Bengbu, AnhuiAges 18–75 - NCT07799116RecruitingPhase 1/Phase 2
Car-t cell therapy for refractory lupus nephritis
This trial tests a new treatment called CD19 CAR-T cell therapy for people with severe lupus nephritis (lupus-related kidney inflammation) that hasn't improved with usual treatments. The therapy uses your own immune cells to target and possibly reset the immune system, which may reduce kidney damage and help control the disease.
Badalona, BarcelonaAges 18–65 - NCT07611214RecruitingPhase 4
LUPKYNIS Combined With Immune-Targeting Drugs for Lupus Kidney Disease
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
La Mesa, CaliforniaAges 18–75 - NCT07598396RecruitingPhase 2
Mosunetuzumab for systemic lupus erythematosus treatment
This study tests a new drug called mosunetuzumab in people with systemic lupus erythematosus (SLE), a disease where the immune system attacks the body's own tissues. The drug is designed to help control the immune response and reduce lupus symptoms, including kidney involvement if present.
Salvador, Estado de BahiaAges 18 years+ - NCT07570862RecruitingPhase 2
CAR T-Cell Therapy for Hard-to-Treat Lupus Kidney Disease
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Beverly Hills, CaliforniaAges 12–70 - NCT02954939Recruiting
Test medicines to change immune cells in lupus kidney flare
This study tests whether mycophenolate mofetil and cyclophosphamide can improve active lupus kidney inflammation by changing immune cell patterns in your blood. It may help patients whose lupus nephritis is currently active, shown by worsening urine protein and/or kidney blood tests.
Hong KongAges 18–80 - NCT07517536Enrolling by invitation
CHT105 treatment for hard-to-treat lupus kidney disease
This study tests a new medicine called CHT105 for lupus patients whose kidney disease hasn't improved with standard treatments. The medicine targets specific immune cells that may be driving the kidney damage.
Nanjing, JiangsuAges 18–65 - NCT06785519RecruitingEarly Phase 1
CAR-T cell therapy for stubborn lupus kidney disease
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07328581RecruitingPhase 2
CAR-T cell therapy for refractory lupus with or without kidney involvement
This trial tests a new treatment called ICG318 CAR-T, which uses your own immune cells to target and calm the overactive immune system in lupus. It may help people whose lupus has not improved with standard treatments, including those with lupus nephritis (kidney inflammation).
Chicago, IllinoisAges 16–70 - NCT07323524RecruitingPhase 4
Dapagliflozin for active lupus kidney disease
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
Boston, MassachusettsAges 18–70 - NCT07201129RecruitingPhase 3
Cenerimod for Active Lupus Nephritis
This trial tests if an investigational drug called cenerimod can safely and effectively treat active lupus nephritis when added to your regular lupus medications. It's for people with recent kidney biopsy showing active lupus kidney disease and high protein in urine.
Doral, FloridaAges 18–75 - NCT07109986RecruitingPhase 1
Study of UB-VV410 for active lupus or lupus nephritis
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
NanjingAges 18–65 - NCT07107659RecruitingEarly Phase 1
Testing ONT01 for active lupus
This trial tests a new drug called ONT01 for people with active lupus that is not affecting their kidneys. It is for those who have not had success with standard treatments.
New York, New YorkAges 18 years+ - NCT07053800RecruitingPhase 2
Obe-cel for severe lupus with kidney inflammation
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
New York, New YorkAges 12–65 - NCT06975787RecruitingPhase 1
A New Bispecific Antibody for Lupus Nephritis
This trial is testing a new type of medicine called a 'bispecific antibody' for people whose lupus nephritis has not responded to standard treatments or keeps coming back. The goal is to find a safe dose that might better control the kidney inflammation.
San Francisco, CaliforniaAges 18–60 - NCT06676631RecruitingPhase 1
NK cells plus rituximab for active lupus
This study tests whether combining immune cells (NK cells) with rituximab can help people with hard-to-treat lupus or lupus-related kidney disease. It is for patients whose lupus is still active despite standard treatments.
Guangzhou, GuangdomgAges 18–65 - NCT04449991Recruiting
Repeat kidney biopsy in new lupus kidney disease
This study looks at whether doing a planned second kidney biopsy about 12 months later helps doctors understand and guide treatment for people with newly diagnosed lupus nephritis. You may be put on standard lupus-kidney medications, and the main “test” is the repeat biopsy timing.
StockholmAges 18 years+ - NCT05201469RecruitingPhase 2
VIB4920 for lupus kidney inflammation not responding well enough
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
La Jolla, CaliforniaAges 18 years+ - NCT03673748RecruitingPhase 2
Mesenchymal stem cell treatment for lupus kidney inflammation
This trial tests whether donated (allogeneic) stem cells can improve lupus nephritis, a kidney complication of lupus. It is for adults whose lupus kidney disease has not responded well to standard treatments or has come back, and it requires signs of active disease.
Valladolid, ValladolidAges 18 years+ - NCT06631404Recruiting
Ultrasound test for lupus kidney activity
This trial uses an ultrasound to measure kidney blood flow in people with lupus kidney disease. The goal is to see if this simple test can tell how active the disease is, which might help doctors adjust treatment without needing frequent biopsies.
SohagAges 18–50 - NCT07700940RecruitingPhase 4
Empagliflozin for kidney function in lupus nephritis
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
Banī SuwayfAges 18–65 - NCT07229742RecruitingPhase 2
Study of SHR-2173 for active lupus nephritis
This trial tests a new medicine called SHR-2173 for people with active lupus nephritis, a kidney inflammation caused by lupus. The goal is to see if it is safe and effective.
Nanjing, JiangsuAges 18–70
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Lupus Nephritis trials by city
Studies with a site in or near these metro areas.
Lupus Nephritis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for lupus nephritis?
- Yes. Clin2 currently lists 79 recruiting lupus nephritis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus nephritis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus nephritis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.